Objective: Single inhaler triple therapy is widely used in Chronic Obstructive Pulmonary Disease (COPD) and asthma. This research aimed to analyze adverse events (AEs ...

Pharmac’s achievements as historic funding enable access to new, life-saving medicines for New Zealanders, Associate Health Minister David Seymour said. Pharmac, New Zealand's medicine ...

Please find the enclosed intimation of the Company as per the captioned subject for your reference.

Meanwhile, Pharmac's decision to fund the budesonide, glycopyrronium and formoterol aerosol inhaler is expected to help 5000 New Zealanders with COPD in the first year of funding, rising to 16,000 ...